Meritage Homes
MTH
KB Home
KBH
D.R. Horton
DHI
4
Adobe
ADBE
5
Lennar Corp
LEN
US Stock MarketDetailed Quotes
STRO Sutro Biopharma
- 1.050
- +0.175+20.04%
Close Apr 30 16:00 ET
- 1.030
- -0.020-1.90%
Post 19:59 ET
87.96MMarket Cap-0.35P/E (TTM)
1.080High0.832Low2.93MVolume0.856Open0.875Pre Close2.83MTurnover4.14%Turnover RatioLossP/E (Static)83.78MShares5.17052wk High1.97P/B74.35MFloat Cap0.52352wk Low--Dividend TTM70.81MShs Float28.300Historical High--Div YieldTTM28.39%Amplitude0.523Historical Low0.965Avg Price1Lot Size
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
Sutro Biopharma Stock Forum
Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025
Monday, 28th April at 4:05 pm
SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced poster presentations at the upcoming 2025 American Association for Cancer Research (...
Sutro's Cancer Drug Doubles Response Rate in Latest Trial, But Faces Uncertain Future
Sutro Biopharma Unveils Major Strategic Shift with $317M War Chest Through 2026
Boehringer Ingelheim And Sutro Biopharma Announced Successful Large-Scale Production Of Luvelta Using Sutro's Cell-Free Expression Technology For Ovarian Cancer Treatment; Achieved Industry Milestone With 4,500L GMP Batches Meeting Clinical Study...
No comment yet